Publication: 4766

Publication: 4766

Tumor Infiltrating Lymphocytes and RNA Sequencing Metrics Associated with Benefit From Microtubule Inhibitor Therapy for Metastatic, HER2-Negative Breast Cancer: A Secondary Analysis of the CALGB 40502 (Alliance) Phase III Randomized Clinical Trial

Google Scholar

Citation:

Meeting Instance:: SABCS 2025
Year:: 2025
Type:: Abstract
Sub type:
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No

Parents:: None
Children:: None

Program:: TRP
Primary Committee:: PPP
Sec. Committees:

Pharmas:: Bristol Myers Squibb (BMS)
Grants:: U10CA180821, U10CA180882, U24CA196171

Corr. Author:
Authors:: Elijah Blige Mark Vater Karla V. Ballman W. Fraser Symmans Mark A. Watson Anna Michmerhuizen Charles M. Perou Daniel G. Stover Hope S. Rugo

Networks:: CA043, LAPS-MO011, LAPS-NC007, LAPS-OH007, LAPS-TX035

Study: CALGB-40502
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: